According to the data and statistics given by MarketResearch.com and Transparency Market Research, the global stem cell market size exceeded $ 40 billion in 2013. The potential market size of the global stem cells medication is expected to reach $119.5 billion in 2018 and reach $400 billion in 2020. So far, 8 kinds of stem cell products have been approved throughout the world, but all come in North America and South Korea. No Chinese products passed. Allegedly, 10 new stem cell drug applications for registration were all rejected by China Food and Drug Administration, with no doubt is a heavy blow to research institutions, technology companies and investors , against their enthusiasm of stem cell researches and industrialization. On 2015 August 21st , National Health and Family Planning Commission, China Food and Drug Administration jointly issued the official Administration of Stem Cell Clinical Research(Trial) online, which is China's first regulatory document for stem cell clinical research. In less than one year’s time, National Health and Family Planning Commission also introduce policies as below: Notice of Establishing the Leading Group of National Stem Cell Clinical Research Administration, Notice of Establishing the Expert Committee of National Stem Cell Clinical Study, and Publicity on Registration of the First Batch of Stem Cell Clinical Research Institutions. All these were released in the first 6 months of 2016, making us wonder if it means the dawn of Chinese stem cell industry has come. In this context, 2nd China Stem Cell Development Summit 2016 will be held in September by Enmore Healthcare. By then, Enmore Healthcare will gather around 300 professionals; invite the government and authority, heads of research institutes and clinical department directors from tertiary Class-A hospitals. From the aspects of the making and interpretation of policy, technology development and application, clinical research and trials, to capital market operation, we will fully explore the development and opportunities of Chinese stem cell industry from both macro and micro level. Look forward to your participation!
ENMORE HEALTHCARE, an independent business unit of ENMORE BIZ, has been engaging in IVD, antibody drug, immunotherapy, vaccine, plasma and other healthcare industries since 2008. It provides industry events, executive search and media promotion service. ENMORE HEALTHCARE is committed to build the service platform of a focus on life sciences and healthcare fields, enhance mutual understanding of international and domestic counterparts, to promote cooperation between enterprises, scientific research and medical institutions, to enhance the communication between the government, association and enterprise.